Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients

Journal of Hepatology

Volumn 47, Issue 3, 2007, Pages 366-372

  Buti, M ^a   Elefsiniotis, I ^a   Jardi, R ^a   Vargas, V ^a   Rodriguez Frias, F ^a   Schapper, M ^a   Bonovas, S ^a   Esteban, R ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Adefovir; Chronic hepatitis B; Genotype; Lamivudine; Viral load

Indexed keywords

ADEFOVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; VIROLOGY; VIRUS LOAD;

ADENINE; ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENE DOSAGE; GENOTYPE; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 34547399523     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.04.011     Document Type: Article

References (33)

1. Lok A.S.F. Chronic hepatitis B. N Engl J Med 346 (2002) 1682-1683
2. Iloeje U., Yang H.I., Su J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (2006) 678-686
3. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
4. Conjeevaram H.S., and Lok A.S.F. Management of chronic hepatitis B. J Hepatol 38 (2003) S90-S103
5. Lai C.L., Chien R.N., Leung N.W.Y., Chang T.T., Guan R., Tai D.I., et al. A one year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339 (1998) 61-68
6. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States.
7. Shaw T., Bowden S., and Locarnini S. Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy?. Gastroenterology 126 (2004) 343-350
8. Lai C.L., Dienstag J.L., Schiff E.R., Leung N.W.Y., Atkins M., Hunt C., et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36 (2003) 687-696
9. Lok A.S.F., Lai C.L., Leung N.W.Y., Yao G.B., Cui Z.Y., Schiff E.R., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 (2003) 1714-1722
10. Leung N.W.Y., Lai C.L., Chang T.T., Guan R., Lee C.M., Ng K.Y., et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33 (2001) 1527-1532
11. Dienstag J.L., Goldin R.D., Heathcote E.J., Hann H.W.L., Woessner M., Stephenson S.L., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124 (2003) 105-117
12. Liaw Y.F., Leung N.W.Y., Chang T.T., Guan R., Tai D.I., Ng K.Y., et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119 (2000) 172-180
13. Marcellin P., Chang T.T., Lim S.G., Tong M., Sievert W., Shiffman M., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
14. Hadziyannis S., Tassopoulos N., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen negative chronic hepatitis B. N Engl J Med 348 (2003) 800-807
15. Peters M.G., Hann H.W., Martin P., Heathcote E.J., Buggisch P., Rubin R., et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126 (2004) 91-101
16. Perrillo R., Hann H.W., Mutimer D., Willems B., Leung N., Lee W.M., et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 126 (2004) 81-90
17. Locarnini S., Qi X., Arterbum S., Snow A., Brosgart C.L., Currie G., et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (abstract). J Hepatol 42 (2005) A17
18. Westland C.E., Yang H., Delaney W.E., Gibbs C.S., Miller M.D., Wulfsohn M., et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 38 (2003) 96-103
19. Lee Y.S., Suh D.J., Lim Y.S., Jung S.W., Kim K.M., Lee H.C., et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43 (2006) 1385-1391
20. Fung S.K., Andreone P., Han S., Reddy K.R., Regev A., Keeffe E.B., et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 43 (2005) 937-943
21. Fung S.K., Chae H.B., Fontana R., Conjeevaram H., Marrero J., Oberhelman K., et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44 (2006) 283-290
22. Lampertico P., Vigano M., Manenti E., Iavarone M., Lunghi G., and Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotyping resistance to lamivudine. Hepatology 42 (2005) 1414-1419
23. Rapti I., Dimou E., Mitsoula P., and Hadziyannis S.J. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45 (2007) 307-313
24. Jardi R, Rodriguez F, Schaper M, Ruiz G, Elefsiniotis I, Esteban R, et al. HBV Polymerase Variants associated with entecavir drug resistance in treatment-nai{dotless}̈ve patients. J Viral Hepat (accepted).
25. Chu C.J., and Lok A.S. Clinical significance of hepatitis B virus genotypes. Hepatology 35 (2002) 1274-1276
26. Sanchez-Tapias J.M., Costa J., Mas A., Bruguera M., and Rodes J. Influence of hepatitis B virus genotype on the long term outcome of chronic hepatitis B in Western patients. Gastoenterology 123 (2002) 1848-1856
27. Janssen H.L., van Zonneveld M., Senturk H., Zeuzem S., Akarca U.S., Cakaloglu Y., et al. Pegylated interferon-alpha 2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 365 (2005) 123-129
28. Buti M., Cotrina M., Valdes A., Jardi R., Rodri{dotless}́guez-Frias F., and Esteban R. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine?. J Hepatol 36 (2002) 445-446
29. Zollner B., Petersen J., Schafer P., Schroter M., Laufs R., Sterneck M., et al. Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment. Clin Infect Dis 34 (2002) 1273-1277
30. Zollner B., Petersen J., Schroter M., Laufs R., Schoder V., and Feucht H.H. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 357 (2001) 934-935
31. Westland C., Delaney W., Yang H., Chen S.S., Marcellin P., Hadziyannis S., et al. Hepatitis B virus genotypes and virological response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 125 (2003) 107-116
32. Tanaka Y., Hasegawa I., Kato T., Orito E., Hirashima N., Acharya S., et al. A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. Hepatology 40 (2004) 747-755
33. Yeon J.E., Yoo W., Hong S.P., Chang Y.J., Yu S.K., Kim J.H., et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 55 (2006) 1488-1495